{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:40:34Z","timestamp":1789958434906,"version":"4.0.1"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012634","name":"Novocure","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.01045","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T01:36:32Z","timestamp":1595900192000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":63,"title":["Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma"],"prefix":"10.3389","volume":"10","author":[{"given":"Mario E.","family":"Lacouture","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan J.","family":"Anadkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Ballo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suriya A.","family":"Jeyapalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato V.","family":"La Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer N.","family":"Serventi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Glas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 world health organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/brainsci7120166","article-title":"Advances in brain tumor surgery for glioblastoma in adults","volume":"7","author":"Lara-Velazquez","year":"2017","journal-title":"Brain Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3389\/fonc.2018.00462","article-title":"Developments in blood-brain barrier penetrance and drug repurposing for improved treatment of glioblastoma","volume":"8","author":"Harder","year":"2018","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/cmi.2017.159","article-title":"Cellular origin of glioblastoma and its implication in precision therapy","volume":"15","author":"Yao","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11060-017-2564-z","article-title":"Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis","volume":"135","author":"Van Linde","year":"2017","journal-title":"J Neurooncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"10152","DOI":"10.1073\/pnas.0702916104","article-title":"Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors","volume":"104","author":"Kirson","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B13","unstructured":"Optune2019"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1158\/0008-5472.CAN-04-0083","article-title":"Disruption of cancer cell replication by alternating electric fields","volume":"64","author":"Kirson","year":"2004","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"18046","DOI":"10.1038\/srep18046","article-title":"Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells","volume":"5","author":"Giladi","year":"2015","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13014-017-0941-6","article-title":"Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells","volume":"12","author":"Giladi","year":"2017","journal-title":"Radiat Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.trsl.2019.10.003","article-title":"Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: implications for cancer therapy","volume":"217","author":"Karanam","year":"2020","journal-title":"Transl Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"65125","DOI":"10.18632\/oncotarget.11372","article-title":"Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/s41419-018-1085-9","article-title":"AMPK-dependent autophagy upregulation serves as a survival mechanism in response to tumor treating fields (TTFields)","volume":"9","author":"Shteingauz","year":"2018","journal-title":"Cell Death Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1158\/1538-7445.AM2017-3665","article-title":"Alternating electric fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy","volume":"196","author":"Giladi","year":"2016","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41420-018-0130-x","article-title":"Tumor treating fields increases membrane permeability in glioblastoma cells","volume":"4","author":"Chang","year":"2018","journal-title":"Cell Death Discov"},{"key":"B22","doi-asserted-by":"publisher","first-page":"vi82","DOI":"10.1093\/neuonc\/noz175.336","article-title":"The blood brain barrier (BBB) permeability is altered by tumor treating fields (TTFields) in vivo","volume":"21","author":"Shulz","year":"2019","journal-title":"Neuro Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12957-015-0722-3","article-title":"NovoTTF-100A system (tumor treating fields) transducer array layout planning for glioblastoma: a NovoTAL system user study","volume":"13","author":"Chaudhry","year":"2015","journal-title":"World J Surg Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.seminoncol.2014.03.011","article-title":"Characterization and management of dermatologic adverse events with the NovoTTF-100A system, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma","volume":"41","author":"Lacouture","year":"2014","journal-title":"Semin Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.ijrobp.2019.04.008","article-title":"Correlation of tumor treating fields dosimetry to survival outcomes in newly diagnosed glioblastoma: a large-scale numerical simulation-based analysis of data from the phase 3 EF-14 randomized trial","volume":"104","author":"Ballo","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B26","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11060-018-03057-z","article-title":"Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial","volume":"141","author":"Toms","year":"2019","journal-title":"J Neurooncol"},{"key":"B27","unstructured":"Optune\u2122 (Formerly NovoTTF-100A\u2122 System) Summary of Safety and Effectiveness Data (SSED)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3390\/cancers11020174","article-title":"Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): a review","volume":"11","author":"Fabian","year":"2019","journal-title":"Cancers."},{"key":"B29","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines2019"},{"key":"B30","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.2015.65.8427","article-title":"Clinical cancer advances 2016: annual report on progress against cancer from the american society of clinical oncology","volume":"34","author":"Dizon","year":"2016","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur J Cancer."},{"key":"B32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaoncol.2017.5082","article-title":"Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial","volume":"4","author":"Taphoorn","year":"2018","journal-title":"JAMA Oncol"},{"key":"B33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-3-319-30576-9_7","article-title":"Tumor treating fields in clinical practice with emphasis on PRiDe registry","volume-title":"Alternating Electric Fields Therapy in Oncology: A Practical Guide to Clinical Applications of Tumor Treating Fields","author":"Ruzevick","year":"2016"},{"key":"B34","doi-asserted-by":"publisher","first-page":"vi139","DOI":"10.1093\/neuonc\/noy148.578","article-title":"INNV-04. Safety and adverse event profile of tumor treating fields in glioblastoma: a global post-market surveillance analysis","volume":"20","author":"Weinberg","year":"2018","journal-title":"Neuro Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1053\/j.seminoncol.2014.09.010","article-title":"Clinical practice experience with NovoTTF-100A\u2122 System for glioblastoma: the patient registry dataset (PRiDe)","volume":"41","author":"Mrugala","year":"2014","journal-title":"Semin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03540-6","article-title":"Global post marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high grade glioma in clinical practice","author":"Shi","year":"2020","journal-title":"J Neurooncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/cid\/ciu444","article-title":"Executive summary: practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B38","first-page":"474","article-title":"Skin and soft tissue infections","volume":"92","author":"Ramakrishnan","year":"2015","journal-title":"Am Fam Phys."},{"key":"B39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-319-30576-9_9","article-title":"Supportive care in patients using tumor treating fields therapy","volume-title":"Alternating Electric Fields Therapy in Oncology: A Practical Guide to Clinical Applications of Tumor Treating Fields","author":"Lacouture","year":"2016"},{"key":"B40","doi-asserted-by":"publisher","first-page":"713","DOI":"10.20471\/acc.2018.57.04.13","article-title":"Irritant and allergic contact dermatitis - skin lesion characteristics","volume":"57","author":"Novak-Bili\u0107","year":"2018","journal-title":"Acta Clin Croat"},{"key":"B41","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s11060-017-2612-8","article-title":"Skin toxicities associated with tumor treating fields: case based review","volume":"135","author":"Lukas","year":"2017","journal-title":"J Neurooncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/jid.2012.511","article-title":"Many paths to alopecia via compromised regeneration of hair follicle stem cells","volume":"133","author":"Li","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2217\/cns-2016-0032","article-title":"A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma","volume":"6","author":"Trusheim","year":"2017","journal-title":"CNS Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1188\/16.CJON.S1.14-19","article-title":"Optune\u00ae: practical nursing applications","volume":"20","author":"Murphy","year":"2016","journal-title":"Clin J Oncol Nurs"},{"key":"B46","doi-asserted-by":"publisher","first-page":"vi3","DOI":"10.1093\/neuonc\/nox168.008","article-title":"ACTR-10. Patterns of TTFields-related severe skin toxicity in GBM patients","volume":"19","author":"Lieberman","year":"2017","journal-title":"Neuro Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e0201957","DOI":"10.1371\/journal.pone.0201957","article-title":"Importance of electrode position for the distribution of tumor treating fields (TTFields) in a human brain. Identification of effective layouts through systematic analysis of array positions for multiple tumor locations","volume":"13","author":"Korshoej","year":"2018","journal-title":"PLoS ONE"},{"key":"B48","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1188\/16.CJON.S1.9-13","article-title":"Efficacy and safety of treating glioblastoma with tumor-treating fields therapy","volume":"20","author":"Saria","year":"2016","journal-title":"Clin J Oncol Nurs"},{"key":"B49","doi-asserted-by":"publisher","first-page":"vi209","DOI":"10.1093\/neuonc\/nox168.845","article-title":"Role of nurses for the implementation of TTFields in daily clinical routine in glioblastoma treatment","volume":"19","author":"Kilias","year":"2017","journal-title":"Neuro Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.soncn.2018.03.005","article-title":"Tumor treating fields technology: alternating electric field therapy for the treatment of solid tumors","volume":"34","author":"Benson","year":"2018","journal-title":"Semin Oncol Nurs"},{"key":"B51","doi-asserted-by":"publisher","first-page":"v189","DOI":"10.1093\/neuonc\/nov230.09","article-title":"QOL-09. Effect of antiperspirants and skin barriers on electrical resistance during TTFields application","volume":"17","author":"Blat","year":"2015","journal-title":"Neuro Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"iii293","DOI":"10.1093\/neuonc\/noy139.293","article-title":"P04.59 Modeling the safety of topical agents for skin toxicity associated with tumor treating fields therapy in glioblastoma","volume":"20","author":"Lacouture","year":"2018","journal-title":"Neuro Oncol"},{"key":"B53","article-title":"Mitigating skin irritations with Tumor Treating Fields therapy in glioblastoma","volume-title":"Oncology Nursing Society's Annual Conference","author":"Lacouture","year":"2018"},{"key":"B54","doi-asserted-by":"publisher","first-page":"vi3","DOI":"10.1093\/neuonc\/nox168.009","article-title":"Overall survival in glioblastoma patients treated with Optune\u00ae correlates with compliance: consistency across studies","volume":"19","author":"Potter","year":"2017","journal-title":"Neuro Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/S1470-2045(19)30532-7","article-title":"Tumour treating fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial","volume":"20","author":"Ceresoli","year":"2019","journal-title":"Lancet Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"vi138","DOI":"10.1093\/neuonc\/noy148.577","article-title":"PROTECT study: prophylactic skin toxicity therapy with clindamycin and clobetasol or skin barrier in glioblastoma patients treated with tumor treating fields","volume":"20","author":"Lacouture","year":"2018","journal-title":"Neuro Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01045\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T08:38:03Z","timestamp":1597048683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01045\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":56,"alternative-id":["10.3389\/fonc.2020.01045"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.01045","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]},"article-number":"1045"}}